Home · English · Breast cancer
TNBC · After chemotherapy · Follow-up
A Normal CT After Chemotherapy: Does It Mean the Breast Cancer Is Gone? How TNBC Follow-Up Works
Symptoms that should not wait for the next CT
A new symptom does not prove that the cancer has returned. It is a reason to tell the team before the appointment.
- Bone pain, abdominal pain, breathlessness, a cough that does not settle, a headache, or a change in vision, when the symptom persists
- A new lump, a change in the breast or chest wall, a nipple change, or a swollen lymph node
- If breathing fails, a seizure starts, one side becomes weak suddenly, bleeding cannot be controlled, or the person collapses, call 1669 in Thailand
Direct answer
A CT without a suspicious lesion is reassuring. It cannot prove that no cancer cells remain below what that scan can show. TNBC follow-up depends on stage, response, residual disease, and symptoms. A CT every 6 months is not the plan for every person without symptoms.
Does a normal CT after chemotherapy mean no cancer remains?
It cannot settle the question at the level of cells. It is good news that the pictures did not show a lesion or abnormality the scanner could display at that time.
CT builds cross-section pictures of the region that was scanned. It is used to look at findings large enough to appear on those images. It does not confirm that no cancer cells remain below what that study can show, and it does not state one person’s future risk. The report has to be read with stage, pathology, surgery, and how the disease responded to treatment.
| What a normal CT can say | What a normal CT cannot say | |
|---|---|---|
| That study | No suspicious finding was seen in the region scanned, and the study can be compared with a later one | It does not say that organs outside the scan were checked |
| The cell level | It reports findings large enough to appear on that study | It does not prove that no cancer cells remain below what the images can show |
| The future | It is good news for the day of the scan | It is not a guarantee that the disease will not return, and it does not replace pathology or stage |
How is NED different from the response after chemotherapy?
These phrases are not interchangeable, and one CT report should not be asked to stand in for all of them.
- No evidence of disease, or NED, is a clinical phrase used when the tests that have been done do not show disease. It is not a lifetime guarantee.
- Pathologic complete response, or pCR, in this guideline means no invasive cancer in the specimen after chemotherapy given before surgery and the operation. Stage II or III TNBC with pCR is placed in the intermediate group.
- Residual disease means invasive cancer is still found after neoadjuvant chemotherapy. TNBC with that finding, within 5 years of diagnosis, is placed in the high-intensity group.
This page does not decide whether a person who reports a normal CT has residual disease. That answer is in the pathology after surgery, not in the feeling of reading a CT report.
How does TNBC follow-up differ from other breast cancers?
TNBC has no estrogen receptor, progesterone receptor, or HER2 target for hormone therapy or HER2-directed drugs. Risk is not set by the subtype name alone. Stage, response, and time since diagnosis change the follow-up group.
The ASCO guideline published online on 16 July 2026 and in print on 20 October 2026 uses history, physical examination, and mammography as the core of follow-up after primary treatment of early-stage breast cancer. No randomized trial compared follow-up schedules by relapse risk. The groups are consensus statements, with low or unrated evidence quality, and the recommendations are conditional. They are not one order for every person.
- The low-intensity group includes TNBC or HER2-positive breast cancer at least 5 years after diagnosis, with a visit once a year.
- The intermediate group includes stage I TNBC within the first 5 years, and stage II or III TNBC with pCR after neoadjuvant therapy. Visits are every 6 to 12 months for 5 to 10 years after diagnosis.
- The high-intensity group includes TNBC with residual disease after neoadjuvant chemotherapy and within 5 years of diagnosis, people with TNBC or HER2-positive disease still on active systemic therapy, and inflammatory breast cancer within 10 years. After active treatment ends, visits in this group are every 3 to 6 months for up to 10 years after diagnosis, then a move to the low-intensity group.
The two time frames are not one number. Membership in the high-intensity group for TNBC with residual disease is limited to within 5 years of diagnosis. The visit cadence written for the high-intensity group runs for up to 10 years. Do not turn those two sentences into a forecast of the year a person’s disease will return.
What is residual disease after chemotherapy before surgery?
It means invasive cancer is still found in the breast or lymph nodes on the specimen after neoadjuvant chemotherapy and surgery. In this guideline that feature raises surveillance intensity, and it may affect treatment after surgery. A later CT is not the test that decides whether residual disease was present.
Side effects during chemotherapy are a different question. The page on TNBC chemotherapy side effects covers that.
Is a CT every 6 months required?
No. That is not one standard for every person.
Recommendation 3.4 says imaging surveillance for distant metastases is not recommended for the overall population of people who have completed breast cancer treatment and who have no symptoms. The discussion says that in an otherwise asymptomatic person with no specific finding on examination, routine intensive imaging is not recommended. The examples named are radionuclide bone scans, chest radiographs, liver ultrasound, CT, and fluorodeoxyglucose PET. The reasons given are false-positive results and the tests that follow them, unnecessary radiation, and financial hardship that can last beyond active treatment.
A visit every 3 to 6 months in the high-intensity group is a history and a physical examination. It is not an order for CT at every visit. That group also suggests a chest-wall examination every 6 months. That is an examination, not a CT.
If a team schedules CT every 6 months, that does not mean the plan is wrong. It means this case has a reason that should be asked about, such as checking response while treatment is still under way, a symptom, or a question left by an older scan. A useful sentence is: in my case, what is the reason for closer imaging than the recommendation for people without symptoms as a group?
If CT is already scheduled, what should be asked?
- Which feature of this case led to this schedule
- Whether the scan is surveillance or a check of response while treatment is still under way
- Which regions are scanned, how long the schedule lasts, and what replaces it later
- Which symptoms should bring imaging sooner than the booked date
- Whether contrast or accumulated radiation is a point the team wants known. The guideline cites unnecessary radiation as a reason not to use distant imaging routinely in people without symptoms. It does not give a home threshold for radiation dose.
Is a mammogram still needed?
The panel recommends annual surveillance mammography for people with TNBC or HER2-positive tumors. That is separate from mammography every 1 to 2 years for some people in the lower-risk group who are 50 or older, with a small, low-grade, estrogen-receptor-positive tumor, and who are free of recurrence at 3 years. Mammo-50, the trial behind the less frequent schedule, had a median age of 66 and mostly estrogen-receptor-positive tumors. It was not powered to separate subtypes, so that wider interval is not applied here to TNBC.
In the intermediate and high-intensity groups, annual mammography is recommended after breast-conserving surgery. After mastectomy on one side, with or without reconstruction, yearly mammography of the remaining breast is indicated. After mastectomy on both sides, the intermediate group says mammography is not recommended unless symptoms warrant it, and the high-intensity group says mammography is not recommended. Those two sentences are not one rule, and they do not mean a reconstructed breast is scanned on a routine calendar.
Breast MRI is supplemental imaging that may be offered after a talk about benefits and harms. The guideline says there is no evidence yet that MRI in post-treatment surveillance improves overall survival. People with a germline mutation, or with radiation to breast tissue between ages 10 and 30, are in the list for considering continued MRI. That is not an order for MRI in every person with TNBC.
Are tumor markers or blood tests required at every visit?
Recommendation 2.1 says routine blood counts, chemistry panels, and the markers CEA, CA 15-3, and CA 27.29 are not recommended for people without symptoms when the purpose is breast cancer surveillance. Evidence quality is low, and the recommendation is conditional. Blood tests can still be ordered for another reason, such as a symptom or a drug effect. This page does not list tests that every person must skip.
Circulating tumor DNA is not recommended for recurrence monitoring outside research. The guideline says it can be associated with risk in some studies, but there is not yet evidence that using it in place of standard follow-up has a net benefit, and a misleading result can increase fear.
Which symptoms should be reported before the next visit?
The guideline says to evaluate promptly when signs appear after primary therapy given with curative intent for early-stage disease. The examples are any change in the size, shape, or appearance of the breast, nipple, or armpit, and any new persistent pain or discomfort, no matter how many years have passed, such as bone pain, abdominal pain, shortness of breath or chest pain, a persistent headache, or a change in vision.
The U.S. National Cancer Institute recurrence page posted on 2 December 2025 adds examples that can go with distant recurrence, including pain that persists, headache, dizziness, seizures, numbness or weakness, breathlessness, a cough that does not settle, trouble swallowing, marked fatigue, yellow skin or eyes, and loss of appetite or weight without a known reason. That page says a symptom or an abnormal image may be recurrence or another condition, so more tests are needed. A symptom alone is not the diagnosis.
The same institute’s general follow-up page, updated 2 December 2024, says a new symptom does not necessarily mean the cancer has come back. In general, across cancers, some people are seen every 3 to 4 months in the first 2 to 3 years, then once or twice a year. That sentence is a general cancer picture. It is not the TNBC schedule, and it is not a CT schedule. The TNBC schedule on this page is the 2026 guideline groups.
Worry before a scan is a known feeling
The living-with-breast-cancer page posted on 2 December 2025 calls the anxiety from follow-up scans scanxiety, and says fear that a pain means the cancer has returned can occur. The feeling is uncomfortable, and it can improve with time and help. A normal CT can reassure someone about what the pictures show. It does not erase the question of cells the pictures cannot show.
A symptom log and a visit plan that has been explained narrow that gap. The page on emotions after cancer treatment discusses fear of recurrence more broadly. It does not answer what a normal TNBC CT means.
What is the core of TNBC follow-up?
| What is watched | What 2026 says | What not to conclude |
|---|---|---|
| History and examination | This is the core in every group. How often depends on the risk group. | It is not a CT at every visit. |
| Mammography | Yearly for TNBC when breast tissue remains, and of the remaining breast after mastectomy on one side. | The 1-to-2-year interval for some lower-risk estrogen-receptor-positive tumors is not the TNBC interval. |
| Imaging when symptoms appear | A persistent symptom or a breast change is a reason for further tests. | A symptom does not prove recurrence. |
| Distant imaging without symptoms | Not recommended for the overall group after treatment is complete. | It does not stop a team from explaining why this case has a CT. |
Prepare questions before the next visit
This button opens the ten questions on this page for a talk with the oncology team. It does not create a new screening tool, and it does not say that one CT means the disease is gone.
Ten questions to ask after TNBC treatment
- Is my result being called a complete response, NED, or is there still residual disease?
- What was the stage before treatment, and what was the stage after surgery?
- What does the pathology after surgery say about recurrence risk?
- Which follow-up intensity group am I in, and why?
- Why is CT scheduled in my case?
- If CT is every 6 months, for how many years, and what changes after that?
- When is a mammogram or a breast MRI needed?
- Are blood tests or tumor markers needed, and for what purpose?
- Which symptoms mean a call or a visit before the appointment?
- What treatment summary and follow-up plan should I keep?
What records should be kept after treatment?
The National Cancer Institute page says a doctor may give a survivorship care plan that lists the treatments and the follow-up plan. Keep a copy.
- The pathology report, the stage, and estrogen, progesterone, and HER2 status
- Genetic results if testing was done
- The chemotherapy regimen and dates, the operation note, the radiation summary, and immunotherapy or targeted therapy if used
- Residual-disease or pCR status, imaging reports, and the visit schedule
Common questions
Does a normal CT after chemotherapy mean the cancer is gone?
No. It means that scan did not show a lesion or abnormality large enough for the images to display. It does not prove that no cancer cells remain below that level.
What does NED mean?
It is a clinical phrase for no evidence of disease on the tests that have been done. It is not a lifetime guarantee, and it is not the same as the pathology result after chemotherapy given before surgery.
Does TNBC require a CT every 6 months?
No. That is not one plan for every person. The 2026 guideline does not recommend imaging to look for distant spread in the overall group of people who have finished treatment and have no symptoms. If a team orders CT, ask why this case is different.
Are tumor markers required in TNBC follow-up?
The guideline does not recommend a blood count, a chemistry panel, or CEA, CA 15-3, and CA 27.29 to watch for recurrence in people without symptoms. Blood tests may still be ordered for another reason.
Why do some people see the team every 3 months?
After active treatment ends, the high-intensity group has a history and physical examination every 3 to 6 months. That is a clinical visit. It is not an order for a CT at every visit.
When does TNBC most often recur?
The guideline does not give one month when recurrence happens for every person. It uses 5 years after diagnosis as the window for high-intensity follow-up in TNBC with residual disease after neoadjuvant chemotherapy, and it moves TNBC at least 5 years from diagnosis into the lower-intensity group. That is not a personal forecast.
Is a mammogram still needed after surgery?
The panel recommends annual surveillance mammography for TNBC when breast tissue remains. After mastectomy on one side, the remaining breast is imaged yearly, with or without reconstruction. After mastectomy on both sides, the intermediate group says mammography is not recommended unless symptoms warrant it, and the high-intensity group says it is not recommended.
How do CT and PET differ in follow-up?
Both are named as routine imaging for distant spread that is not recommended in people without symptoms and without a finding on examination. When there is a reason to image, the team chooses the test.
Which symptoms should be reported before the next visit?
A change in the breast, nipple, or armpit, persistent bone or abdominal pain, breathlessness or chest pain, a persistent headache or a change in vision, a cough that does not settle, marked fatigue, or weight loss without a known reason. These symptoms do not prove that the cancer has returned.
What is scanxiety?
It is worry stirred by scans that are part of follow-up. The U.S. National Cancer Institute page posted on 2 December 2025 says the feeling can occur and can improve with time and help. A normal result can reassure someone about what the pictures show. It does not erase every remaining question.
How the author separates a normal scan from the follow-up plan
Asst. Prof. Dr. Norawit Raatpiboon separates three layers. First, a CT reports what that study can show. It does not prove the cell level. Second, TNBC is grouped by stage, pCR or residual disease, and time since diagnosis, not by the subtype name alone. Third, closer visits are not the same as a CT every 6 months. Distant imaging in people without symptoms is not recommended for the overall group.
Sources read for this page
- ASCO breast cancer follow-up and surveillance guideline, online 16 July 2026, in print 20 October 2026
- NCI living with breast cancer, posted 2 December 2025
- NCI symptoms that can go with recurrence, posted 2 December 2025
- NCI follow-up care across cancers, updated 2 December 2024
Limits of this page
This page is general information for adults. It does not say that one CT proves no cancer cells remain. It does not say every person with TNBC needs a CT every 6 months, and it does not decide that someone who describes a normal scan has residual disease. If breathing fails, a seizure starts, one side becomes weak suddenly, or the person collapses, call 1669 in Thailand.